• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Amphetamines Stand Out in ADHD

Amphetamines Stand Out in ADHD

March 29, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Michael Posternak, MD.

Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Cortese S et al, Lancet 208;5:727–738
Type of study: Meta-analysis

With so many medications available to treat ADHD, wouldn’t it be nice to know if some are better than others? In this comprehensive meta-analysis, researchers sought to compare the relative efficacy and tolerability of both stimulant (methylphenidate and amphetamines) and non-stimulant (atomoxetine, bupropion, modafinil, clonidine, and guanfacine) medications for ADHD in children and adults.


The investigators combed through published and unpublished databases and located 82 double-blind, randomized controlled trials in children and adolescents, and 52 such trials in adults. Together, they included over 10,000 children and adolescents, and over 8,000 adults. The primary outcome was change in ­clinician-rated ADHD symptoms, while teacher ratings were also evaluated for children. “Tolerability” was defined as the percentage who dropped out because of side effects, while the broader term “acceptability” referred to those who dropped out for any reason. Outcomes were evaluated through 12 weeks of treatment.

In children and adolescents, all medications were superior to placebo. Amphetamines emerged as the most effective ADHD medication, superior to modafinil, guanfacine, atomoxetine, and methylphenidate. Methylphenidate was superior to atomoxetine. Based on teacher ratings, only methylphenidate and modafinil separated from placebo (none of the amphetamine trials included teacher ratings). With respect to tolerability, amphetamines and guanfacine both displayed significantly more adverse effects than placebo; amphetamines also significantly increased diastolic blood pressure. Methylphenidate was better-tolerated than the amphetamines, and it was the only medication with better acceptability than placebo.

In adults, amphetamines emerged not only as the most efficacious agents but also the only ones with better acceptability than placebo. Methylphenidate, atomoxetine, and bupropion all had similar effect sizes. Clonidine and guanfacine did not have data in adults, and modafinil was ineffective in this population, despite having positive results in children. Tolerability was similar among the agents. In contrast to their effects on children, amphetamines did not increase diastolic blood pressure in adults. Overall, ADHD medications were less efficacious and less well-tolerated in adults than in children and adolescents.

What are the weaknesses? There was a dearth of head-to-head trials, so these comparisons could only be made indirectly. The dropout rate was used as a proxy for acceptability, and this is a rough estimate. Finally, while the large sample sizes instill greater confidence in the results, they also risk finding significant differences that may not necessarily be clinically meaningful.

TCPR’s Take
It’s rare for one medication to stand out in its class, but the amphetamines clearly emerged as the most effective option in both children and adults. That does not mean they should always be first choice, though. Methylphenidate was a more tolerable option in children, and there will always be patients who respond better to the methylphenidate varieties. Non-­stimulant options take longer to work, but they performed fairly well in this ­meta-analysis, sometimes rivaling methylphenidate’s benefits. The only failure was modafinil, which worked in children but not adults.

General Psychiatry
KEYWORDS adhd amphetamines research-update
Michael Posternak, MD.

Adjuvant Clonidine for Mania

More from this author
www.thecarlatreport.com
Issue Date: March 29, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Parenting, Pregnancy, and Prevention, TCPR, March 2019
Ask the Editor: Should You Prescribe Lithium to Suicidal Patients?
Amphetamines Stand Out in ADHD
What Can Our Pregnant Patients Do to Prevent Mental Illness in Their Children?
Parenting Strategies for Patients With Mental Illness
A Second Look at Genetic Testing
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.